ArticleBMC infectious diseases2026
Association of Blastocystis species subtypes 3 and 4 with intestinal inflammation and response to metronidazole in symptomatic patients.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBlastocystis spp. (BC) often passes as a harmless resident of the gut. However, it may be associated with gastrointestinal disturbances, such as abdominal pain and diarrhea. The variation in the clinical spectrum of BC infection is, in part, due to its diverse genotypic profile, where ongoing research continues to discover new BC subtypes. This study aimed at investigating the association between different BC subtypes and intestinal inflammation as assessed by fecal calprotectin (FCP) and tumor necrosis factor alpha (TNF-α) levels.
methodsPatients complaining of gastrointestinal tract (GIT) symptoms were investigated for the presence of BC infection by microscopy and stool culture on Jones’ medium. Out of 163 patients, 88 were confirmed to be infected with BC. They were further divided according to the dominant BC subtype by RFLP genotyping. Patients were treated with metronidazole at a dose of 250 mg 3 times daily for ten days and were evaluated for symptom improvement after the treatment course. Moreover, FCP and TNF-α levels were measured in stool samples by ELISA before and after therapy.
resultsBC subtype 3 was found to be the dominant subtype in 62 samples (70.5%), while subtype 4 was dominant in 26 samples (29.5%). A higher number of patients infected with BC subtype 3 reported the presence of GIT manifestations. After treatment, 17 subtype 3-infected patients (27.4%) witnessed improvement of their GIT symptoms, as compared to 9 patients infected with BC subtype 4 (34.6%). In subtype 3 infected patients, 71% were free of BC stages by both microscopic examination and stool culture, while 92.3% of patients infected with subtype 4 showed fecal parasite clearance. FCP and TNF-α levels were higher in patients infected with BC subtype 3 as compared to BC subtype 4, both before and after treatment with metronidazole. In the BC subtype 3-infected groups, fecal TNF-α and FCP levels decreased significantly after treatment.
conclusionIn our cohort study, BC subtype 3 was the most prevalent subtype among patients reporting gastrointestinal symptoms. The ST3 group exhibited numerically higher inflammatory markers compared to ST4. These trends shed light on the potential link between Blastocystis genetic diversity and intestinal inflammation. Although the observational nature of this study and the unequal group sizes limit the ability to establish a definitive causal relationship, these findings provide a BC subtype-oriented diagnostic and therapeutic design within a hospital-based setting that could facilitate the design of more tailored management strategies for patients with BC-associated symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.